Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107336 | 0.91 | PTPN1 (0.34) | HDAC1HDAC6HDAC5HDAC8KDR | |
| SCHEMBL9105480 | 0.89 | PTPN1 (0.38) | MAPT | |
| SCHEMBL9106229 | 0.89 | MAPT (0.41) | L3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL9109831 | 0.88 | PTPN1 (0.42) | ALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL9105461 | 0.87 | MAPT (0.40) | ALDH1A1L3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL9109029 | 0.87 | TSHR (0.36) | TP53MAPT | |
| SCHEMBL9109162 | 0.87 | PTPN1 (0.36) | MAPTSMN1; SMN2 | |
| SCHEMBL9104028 | 0.85 | S1PR3 (0.38) | L3MBTL1KCNA5MAPTSMN1; SMN2 | |
| SCHEMBL10064874 | 0.85 | PTPN1 (0.35) | TP53MAPT | |
| SCHEMBL9106709 | 0.85 | PTPN1 (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646027-B1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646027-B1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8492410-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492410-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130150411-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150411-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8399492-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399492-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120142736-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142736-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150411-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MDM2 4218/4885HDAC1 1919/4885HDAC6 2520/4885 |
| US-20120142736-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MDM2 4218/4885HDAC1 1919/4885HDAC6 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.